221 related articles for article (PubMed ID: 27566040)
1. Is complete cytoreductive surgery feasible in this patient with ovarian cancer?
Dessapt AL; Huchon C; Ngo C; Bats AS; Bensaid C; Lecuru F
Surg Oncol; 2016 Sep; 25(3):326-31. PubMed ID: 27566040
[TBL] [Abstract][Full Text] [Related]
2. Value of tertiary cytoreductive surgery in epithelial ovarian cancer: an international multicenter evaluation.
Fotopoulou C; Zang R; Gultekin M; Cibula D; Ayhan A; Liu D; Richter R; Braicu I; Mahner S; Harter P; Trillsch F; Kumar S; Peiretti M; Dowdy SC; Maggioni A; Trope C; Sehouli J
Ann Surg Oncol; 2013 Apr; 20(4):1348-54. PubMed ID: 23054114
[TBL] [Abstract][Full Text] [Related]
3. Secondary Cytoreduction in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Institution Experience.
Musella A; Marchetti C; Palaia I; Perniola G; Giorgini M; Lecce F; Vertechy L; Iadarola R; De Felice F; Monti M; Muzii L; Angioli R; Panici PB
Ann Surg Oncol; 2015 Dec; 22(13):4211-6. PubMed ID: 25801357
[TBL] [Abstract][Full Text] [Related]
4. "The impact of debulking surgery in patients with node-positive epithelial ovarian cancer: Analysis of prognostic factors related to overall survival and progression-free survival after an extended long-term follow-up period".
Pereira A; Pérez-Medina T; Magrina JF; Magtibay PM; Rodríguez-Tapia A; Cuesta-Guardiola T; Peregrin I; Mendizabal E; Lizarraga S; Ortiz-Quintana L
Surg Oncol; 2016 Mar; 25(1):49-59. PubMed ID: 26979641
[TBL] [Abstract][Full Text] [Related]
5. A pre-operative predictive score to evaluate the feasibility of complete cytoreductive surgery in patients with epithelial ovarian cancer.
Chesnais M; Lecuru F; Mimouni M; Ngo C; Fauconnier A; Huchon C
PLoS One; 2017; 12(11):e0187245. PubMed ID: 29117194
[TBL] [Abstract][Full Text] [Related]
6. En bloc pelvic resection for advanced ovarian cancer preceded by central ligation of vessels supplying the tumor bed: a description of surgical technique and a feasibility study.
Sznurkowski JJ
World J Surg Oncol; 2016 Apr; 14():133. PubMed ID: 27130224
[TBL] [Abstract][Full Text] [Related]
7. Prediction of suboptimal cytoreductive surgery in patients with advanced ovarian cancer based on preoperative and intraoperative determination of the peritoneal carcinomatosis index.
Llueca A; Serra A; Rivadulla I; Gomez L; Escrig J;
World J Surg Oncol; 2018 Feb; 16(1):37. PubMed ID: 29471831
[TBL] [Abstract][Full Text] [Related]
8. Nomogram for suboptimal cytoreduction at primary surgery for advanced stage ovarian cancer.
Gerestein CG; Eijkemans MJ; Bakker J; Elgersma OE; van der Burg ME; Kooi GS; Burger CW
Anticancer Res; 2011 Nov; 31(11):4043-9. PubMed ID: 22110240
[TBL] [Abstract][Full Text] [Related]
9. Tertiary Cytoreduction for Recurrent Epithelial Ovarian Cancer: a Multicenter Study in Turkey.
Arvas M; Salihoglu Y; Sal V; Gungor T; Sozen H; Kahramanoglu I; Topuz S; Demirkiran F; Iyibozkurt C; Bese T; Ozgu BS; Vatansever D; Tokgozoglu N; Berkman S; Turan H; Bengisu E; Sofiyeva N; Demiral I; Meydanli M
Asian Pac J Cancer Prev; 2016; 17(4):1909-15. PubMed ID: 27221875
[TBL] [Abstract][Full Text] [Related]
10. Liver resection for ovarian cancer liver metastases as part of cytoreductive surgery is safe and may bring survival benefit.
Bacalbasa N; Dima S; Brasoveanu V; David L; Balescu I; Purnichescu-Purtan R; Popescu I
World J Surg Oncol; 2015 Aug; 13():235. PubMed ID: 26243426
[TBL] [Abstract][Full Text] [Related]
11. Impact of complete cytoreduction leaving no gross residual disease associated with radical cytoreductive surgical procedures on survival in advanced ovarian cancer.
Chang SJ; Bristow RE; Ryu HS
Ann Surg Oncol; 2012 Dec; 19(13):4059-67. PubMed ID: 22766983
[TBL] [Abstract][Full Text] [Related]
12. Associations between residual disease and survival in epithelial ovarian cancer by histologic type.
Melamed A; Manning-Geist B; Bregar AJ; Diver EJ; Goodman A; Del Carmen MG; Schorge JO; Rauh-Hain JA
Gynecol Oncol; 2017 Nov; 147(2):250-256. PubMed ID: 28822556
[TBL] [Abstract][Full Text] [Related]
13. The INTERNATIONAL MISSION study: minimally invasive surgery in ovarian neoplasms after neoadjuvant chemotherapy.
Fagotti A; Gueli Alletti S; Corrado G; Cola E; Vizza E; Vieira M; Andrade CE; Tsunoda A; Favero G; Zapardiel I; Pasciuto T; Scambia G
Int J Gynecol Cancer; 2019 Jan; 29(1):5-9. PubMed ID: 30640676
[TBL] [Abstract][Full Text] [Related]
14. Maximal cytoreduction in patients with FIGO stage IIIC to stage IV ovarian, fallopian, and peritoneal cancer in day-to-day practice: a Retrospective French Multicentric Study.
Luyckx M; Leblanc E; Filleron T; Morice P; Darai E; Classe JM; Ferron G; Stoeckle E; Pomel C; Vinet B; Chereau E; Bergzoll C; Querleu D
Int J Gynecol Cancer; 2012 Oct; 22(8):1337-43. PubMed ID: 22964527
[TBL] [Abstract][Full Text] [Related]
15. Results of optimal debulking surgery with bowel resection in patients with advanced ovarian cancer.
Derlatka P; Sienko J; Grabowska-Derlatka L; Palczewski P; Danska-Bidzinska A; Bidzinski M; Czajkowski K
World J Surg Oncol; 2016 Feb; 14():58. PubMed ID: 26923029
[TBL] [Abstract][Full Text] [Related]
16. Improved Postoperative Pain Control for Cytoreductive Surgery in Women With Ovarian Cancer Using Patient-Controlled Epidural Analgesia.
Oh TK; Lim MC; Lee Y; Yun JY; Yeon S; Park SY
Int J Gynecol Cancer; 2016 Mar; 26(3):588-93. PubMed ID: 26825838
[TBL] [Abstract][Full Text] [Related]
17. Prognostic impact of additional extended surgical procedures in advanced-stage primary ovarian cancer.
Kommoss S; Rochon J; Harter P; Heitz F; Grabowski JP; Ewald-Riegler N; Haberstroh M; Neunhoeffer T; Barinoff J; Gomez R; Traut A; du Bois A
Ann Surg Oncol; 2010 Jan; 17(1):279-86. PubMed ID: 19898901
[TBL] [Abstract][Full Text] [Related]
18. A risk model for secondary cytoreductive surgery in recurrent ovarian cancer: an evidence-based proposal for patient selection.
Tian WJ; Chi DS; Sehouli J; Tropé CG; Jiang R; Ayhan A; Cormio G; Xing Y; Breitbach GP; Braicu EI; Rabbitt CA; Oksefjell H; Fotopoulou C; Meerpohl HG; du Bois A; Berek JS; Zang RY; Harter P
Ann Surg Oncol; 2012 Feb; 19(2):597-604. PubMed ID: 21732142
[TBL] [Abstract][Full Text] [Related]
19. Implementation of Extensive Cytoreduction Resulted in Improved Survival Outcomes for Patients with Newly Diagnosed Advanced-Stage Ovarian, Tubal, and Peritoneal Cancers.
Raspagliesi F; Bogani G; Ditto A; Martinelli F; Chiappa V; Borghi C; Scaffa C; Morano F; Maltese G; Lorusso D
Ann Surg Oncol; 2017 Oct; 24(11):3396-3405. PubMed ID: 28795373
[TBL] [Abstract][Full Text] [Related]
20. Serum HE4 superior to CA125 in predicting poorer surgical outcome of epithelial ovarian cancer.
Shen Y; Li L
Tumour Biol; 2016 Nov; 37(11):14765-14772. PubMed ID: 27629144
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
